Page last updated: 2024-09-03

gefitinib and floxuridine

gefitinib has been researched along with floxuridine in 4 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(floxuridine)
Trials
(floxuridine)
Recent Studies (post-2010) (floxuridine)
5,2315662,9193,556323280

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)floxuridine (IC50)
Thymidylate synthaseMus musculus (house mouse)1.0862

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Ekins, S; Williams, AJ; Xu, JJ1
Ciccolini, J; Dubreuil, A; Etienne, MC; Fischel, JL; Formento, JL; Formento, P; Magné, N; Marchetti, S; Milano, G; Renée, N; Tiffon, C1
Ait-Tihyaty, M; Jean-Claude, BJ; Mihalcioiu, C; Rachid, Z1

Other Studies

4 other study(ies) available for gefitinib and floxuridine

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-15, Volume: 9, Issue:13

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Primers; Floxuridine; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Models, Chemical; Polymerase Chain Reaction; Pyrimidines; Quinazolines; RNA; RNA, Messenger; Time Factors; Transcription, Genetic

2003
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.
    Breast cancer research and treatment, 2012, Volume: 133, Issue:1

    Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; ErbB Receptors; Female; Floxuridine; Fluorouracil; Gefitinib; Gene Expression Regulation, Enzymologic; Humans; Inhibitory Concentration 50; Methotrexate; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Thymidine Phosphorylase; Thymidylate Synthase

2012